» Articles » PMID: 38375478

Location Matters: Spatial Dynamics of Tumor-infiltrating T Cell Subsets is Prognostic in Colon Cancer

Abstract

Background: Colon cancer is a heterogeneous disease and consists of various molecular subtypes. Despite advances in high-throughput expression profiling, limitations remain in predicting clinical outcome and assigning specific treatment to individual cases. Tumor-immune interactions play a critical role, with tumors that activate the immune system having better outcome for the patient. The localization of T cells within tumor epithelium, to enable direct contact, is essential for antitumor function, but bulk DNA/RNA sequencing data lacks spatial distribution information. In this study, we provide spatial T cell tumor distribution and connect these data with previously determined genomic data in the AC-ICAM colon cancer patient cohort.

Methods: Colon cancer patients (n=90) with transcriptome data available were selected. We used a custom multiplex immunofluorescence assay on colon tumor tissue sections for quantifying T cell subsets spatial distribution in the tumor microenvironment, in terms of cell number, location, mutual distance, and distance to tumor cells. Statistical analyses included the previously determined Immunologic Constant of Rejection (ICR) transcriptome correlation and patient survival, revealing potential prognostic value in T cell spatial distribution.

Results: T cell phenotypes were characterized and CD3CD8FoxP3 T cells were found to be the predominant tumor-infiltrating subtype while CD3FoxP3 T cells and CD3CD8 T cells showed similar densities. Spatial distribution analysis elucidated that proliferative T cells, characterized by Ki67 expression, and Granzyme B-expressing T cells were predominantly located within the tumor epithelium. We demonstrated an increase in immune cell density and a decrease in the distance of CD3CD8 T cells to the nearest tumor cell, in the immune active, ICR High, immune subtypes. Higher densities of stromal CD3FoxP3 T cells showed enhanced survival outcomes, and patients exhibited superior clinical benefits when greater spatial distances were observed between CD3CD8FoxP3 or CD3CD8 T cells and CD3FoxP3 T cells.

Conclusion: Our study's in-depth analysis of the spatial distribution and densities of major T cell subtypes within the tumor microenvironment has provided valuable information that paves the way for further research into the intricate relationships between immune cells and colon cancer development.

Citing Articles

Association between somatic microsatellite instability, hypermutation status, and specific T cell subsets in colorectal cancer tumors.

Thomas C, Takashima Y, Wesselink E, Ugai T, Steinfelder R, Buchanan D Front Immunol. 2025; 15:1505896.

PMID: 39763680 PMC: 11701007. DOI: 10.3389/fimmu.2024.1505896.


Mapping intratumoral myeloid-T cell interactomes at single-cell resolution reveals targets for overcoming checkpoint inhibitor resistance.

Bridges K, Pizzurro G, Baysoy A, Baskaran J, Xu Z, Mathew V bioRxiv. 2024; .

PMID: 39554094 PMC: 11565996. DOI: 10.1101/2024.10.28.620093.


Colon Cancer Disease Diagnosis Based on Convolutional Neural Network and Fishier Mantis Optimizer.

Mohamed A, Hancerliogullari A, Rahebi J, Rezaeizadeh R, Lopez-Guede J Diagnostics (Basel). 2024; 14(13).

PMID: 39001307 PMC: 11241213. DOI: 10.3390/diagnostics14131417.

References
1.
Weigelin B, den Boer A, Wagena E, Broen K, Dolstra H, De Boer R . Cytotoxic T cells are able to efficiently eliminate cancer cells by additive cytotoxicity. Nat Commun. 2021; 12(1):5217. PMC: 8410835. DOI: 10.1038/s41467-021-25282-3. View

2.
McKenzie S, Nelson R, Mailey B, Lee W, Chung V, Shibata S . Adjuvant chemotherapy improves survival in patients with American Joint Committee on Cancer stage II colon cancer. Cancer. 2011; 117(24):5493-9. DOI: 10.1002/cncr.26245. View

3.
Toth Z, Mezey E . Simultaneous visualization of multiple antigens with tyramide signal amplification using antibodies from the same species. J Histochem Cytochem. 2007; 55(6):545-54. DOI: 10.1369/jhc.6A7134.2007. View

4.
Tokunaga R, Zhang W, Naseem M, Puccini A, Berger M, Soni S . CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. Cancer Treat Rev. 2017; 63:40-47. PMC: 5801162. DOI: 10.1016/j.ctrv.2017.11.007. View

5.
Roelands J, Kuppen P, Ahmed E, Mall R, Masoodi T, Singh P . An integrated tumor, immune and microbiome atlas of colon cancer. Nat Med. 2023; 29(5):1273-1286. PMC: 10202816. DOI: 10.1038/s41591-023-02324-5. View